LexaGene Closes Multiple MiQLab Sales
December 03 2021 - 7:45AM
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the
“
Company”), a molecular diagnostics company that
develops fully automated rapid pathogen detection systems, is
pleased to announce two purchase orders from Kuma Veterinary Clinic
and the Emergency Veterinary Services of Roanoke.
Dr. Jack Regan, LexaGene’s Founder and CEO commented, “I’m
pleased to announce that we have closed additional MiQLab System
sales to private hospitals. Veterinarians are learning more about
our system and recognizing how wrong it is to have to wait days to
weeks for a reference lab to provide infectious disease results
that can impact the well-being of their patients. Our MiQLab System
provides them a solution to this problem, as it delivers
high-quality results at the point of need in just ~2 hours. This
time savings empowers them to make evidence-based decisions to
improve the quality of the care they provide.”
Gwyneth Shugart, CVT and co-owner of Kuma Veterinary Clinic
commented, “We purchased the MiQLab system to offer better services
to our clients and the pets they love. Too often, slow diagnostics
have prevented us from more rapidly improving our patients’ health,
which has led to frustration, unnecessary pain and suffering, and
higher costs. It is truly exciting to have this new diagnostic in
our hospital, as we put the days of practicing medicine based on
empiric diagnosis behind us.”
Julie Griggs, CVT, LexaGene’s Global Director of Sales stated,
“The vast majority of specialty and 24-hour emergency veterinary
hospitals are no longer private and are consolidated or owned by
large corporations. Over the last two months we’ve made good
progress in the sales cycle for large corporations, where we target
multi-unit sales. We expect the corporate sales will start a wave
of adoption across the industry as veterinary practices will not
want to be left behind and will seek to modernize their technology
to keep up with the expectations of their clients and new industry
standards.”
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
About LexaGene Holdings Inc.LexaGene develops
molecular diagnostic systems for pathogen detection and genetic
testing for other molecular markers for on-site rapid testing in
veterinary diagnostics, food safety and for use in open-access
markets such as clinical research, agricultural testing, and
biodefense. End-users simply need to collect a sample, load it onto
the instrument with a sample preparation cartridge, enter sample ID
and press ‘go’. The MiQLab™ system delivers excellent sensitivity,
specificity, and breadth of detection and can return results in
approximately two hours. The unique open-access feature is designed
for custom testing so that end-users can load their own real-time
PCR assays onto the instrument to target any genetic target of
interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Corporate & Media Contact:
Gail Winslow
Director, Marketing
gwinslow@lexagene.com
978.482.6237
Investors:
ir@lexagene.com
800.215.1824
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024